GREGORY WEAVER

Corporate Board Profile

Tech Score: 0/100

Imunon, Inc.

Filing Date	Source Excerpt
2010-04-30	Mr. Weaver earned his MBA from Boston College and B.S. in accounting from Trinity University and was a certified public accountant. The Board of Directors concluded that Mr. Weaver should continue to serve as a director on account of, among other things, the following experience, qualifications, attributes, and skills: Leadership attributes and management experience, including executive positions with several companies in the pharmaceutical and biotechnology industries; Experience with financial reporting by public companies; Professional and educational background.
2011-04-29	Mr. Weaver served as Chief Financial Officer of Talyst, Inc., a privately-held pharmacy information product company, from 2007 to 2008. Prior to that, he served as Senior Vice President and Chief Financial Officer of Sirna Therapeutics, a public RNAI therapeutics company until the sale of the company to Merck, Inc. in 2006. From 2002 to 2005, Mr. Weaver was Chief Financial Officer and Corporate Secretary of Nastech Pharmaceuticals, a public drug delivery company. From 1999 to 2002, Mr. Weaver was Chief Financial Officer of Ilex Oncology Inc., a public cancer drug development company, and from 1996 to 1998, he was Chief Financial Officer of Prism Technologies, a privately-held medical device manufacturer. Mr. Weaver is a certified public accountant and received his MBA from Boston College and his B.S. in accounting from Trinity University.

Filing Date

Source Excerpt

2010-04-30

Mr. Weaver earned his MBA from Boston College and B.S. in accounting from Trinity University and was a certified public accountant. The Board of Directors concluded that Mr. Weaver should continue to serve as a director on account of, among other things, the following experience, qualifications, attributes, and skills: Leadership attributes and management experience, including executive positions with several companies in the pharmaceutical and biotechnology industries; Experience with financial reporting by public companies; Professional and educational background.

2011-04-29

Mr. Weaver served as Chief Financial Officer of Talyst, Inc., a privately-held pharmacy information product company, from 2007 to 2008. Prior to that, he served as Senior Vice President and Chief Financial Officer of Sirna Therapeutics, a public RNAI therapeutics company until the sale of the company to Merck, Inc. in 2006. From 2002 to 2005, Mr. Weaver was Chief Financial Officer and Corporate Secretary of Nastech Pharmaceuticals, a public drug delivery company. From 1999 to 2002, Mr. Weaver was Chief Financial Officer of Ilex Oncology Inc., a public cancer drug development company, and from 1996 to 1998, he was Chief Financial Officer of Prism Technologies, a privately-held medical device manufacturer. Mr. Weaver is a certified public accountant and received his MBA from Boston College and his B.S. in accounting from Trinity University.

VERIZON COMMUNICATIONS INC

Filing Date	Source Excerpt
2023-03-27	Twice elected by fellow partners to serve as Chairman and CEO of Deloitte & Touche LLP’s audit and enterprise risk services practice in the U.S., overseeing all operations, regulatory interaction and quality control for all audit and risk consulting clients.

Data sourced from SEC filings. Last updated: 2025-07-01